Abdel-Razeq Hikmat, Almasri Hanan, Abdel Rahman Fadwa, Abdulelah Hazem, Abu Nasser Mahmoud, Salam Mourad, Al-Dairi Ammer, Natour Osama, Rimawi Dalia
Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
School of Medicine, University of Jordan, Amman, Jordan.
Cancer Manag Res. 2019 Nov 22;11:9891-9897. doi: 10.2147/CMAR.S229337. eCollection 2019.
Compared to Western societies, breast cancer diagnosis in our region is usually made at a younger age and at a more advanced stage. Breast cancer in younger patients tends to be more aggressive, and may result in a higher likelihood of long-term treatment-related toxicity and unique psychosocial problems. This study highlights the clinicopathological features and treatment outcomes in this age-group in a developing country like ours.
Consecutive patients aged 40 years or younger with a pathologically confirmed diagnosis of breast cancer treated and followed up at our institution were included. Medical records and hospital databases were searched for patients' characteristics and treatment outcomes.
A total of 417 patients were enrolled. Median age at diagnosis was 35 (21-40) years. On presentation, 63 (15.1%) patients had metastatic disease, 50 (79.4%) with visceral metastasis. Patients with nonmetastatic disease had poor pathological features, including node-positivity (66.9%), grade III (51.4%), lymphovascular invasion (48.6%) and positive HER2 (31.5%). Breast-conserving surgery was performed on 32.9%, and only 36.5% of women had breast-reconstruction surgery. At a median follow-up of 59 months, 5-year overall survival for the whole group was 72%: 84% for nonmetastatic and 13% for those with metastatic disease. On Cox regression, nodal metastasis (adjusted HR 3.46, 95% CI 1.48-8.10; =0.004) and grade III disease (HR 1.97, 95% CI 1.14-3.39; =0.015) were associated with poor outcome.
Adolescents and young Jordanian adults with breast cancer present with more advanced-stage disease and more aggressive pathological features that reflect poorly on treatment outcomes.
与西方社会相比,我们地区乳腺癌的诊断通常在更年轻的年龄且处于更晚期阶段。年轻患者的乳腺癌往往更具侵袭性,可能导致长期治疗相关毒性和独特心理社会问题的可能性更高。本研究强调了在像我们这样的发展中国家该年龄组的临床病理特征和治疗结果。
纳入在我们机构接受治疗并随访的年龄40岁及以下经病理确诊为乳腺癌的连续患者。检索病历和医院数据库以获取患者特征和治疗结果。
共纳入417例患者。诊断时的中位年龄为35(21 - 40)岁。初诊时,63例(15.1%)患者有转移性疾病,50例(79.4%)有内脏转移。非转移性疾病患者具有不良病理特征,包括淋巴结阳性(66.9%)、III级(51.4%)、淋巴管浸润(48.6%)和HER2阳性(31.5%)。32.9%的患者接受了保乳手术,只有36.5%的女性进行了乳房重建手术。中位随访59个月时,全组5年总生存率为72%:非转移性患者为84%,转移性疾病患者为13%。在Cox回归分析中,淋巴结转移(调整后HR 3.46,95%CI 1.48 - 8.10;P = 0.004)和III级疾病(HR 1.97,95%CI 1.14 - 3.39;P = 0.015)与不良预后相关。
约旦青少年和年轻成年乳腺癌患者表现为更晚期疾病和更具侵袭性的病理特征,这对治疗结果反映不佳。